514 Federal Register / Vol. 80, No. 3 / Tuesday, January 6, 2015 / Notices 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; 

Therapeutic Agents that Target Cancer Stem 

Cells. 

Date: March 10–11, 2015. 

Time: 11:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute Shady 

Grove, 9609 Medical Center Drive, Room 

4W032, Rockville, MD 20850 (Telephone 

Conference Call). 

Contact Person: Kenneth L. Bielat, Ph.D., 

Scientific Review Officer, Research 

Technology and Contract Review Branch, 

Division of Extramural Activities, National 

Cancer Institute, 9609 Medical Center Drive, 

Room 7W244, Bethesda, MD 20892–9750, 

240–276–6373, bielatk@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Innovative 

Research in Cancer Nanotechnology (IRCN). 

Date: March 19–20, 2015. 

Time: 8:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel and 

Conference Center 5701 Marinelli Road 

Bethesda, MD 20852. 

Contact Person: Kenneth L. Bielat, Ph.D., 

Scientific Review Officer, Research 

Technology and Contract Review Branch, 

Division of Extramural Activities, National 

Cancer Institute, 9609 Medical Center Drive, 

Room 7W244, Bethesda, MD 20892–9750, 

240–276–6373, bielatk@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Advance 

Culture Systems for Expansion of Cancer 

Stem Cells. 

Date: March 25–26, 2015. 

Time: 11:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute Shady 

Grove, 9609 Medical Center Drive, Room 

2E032, Rockville, MD 20850, (Telephone 

Conference Call). 

Contact Person: Kenneth L. Bielat, Ph.D., 

Scientific Review Officer, Research 

Technology and Contract Review Branch, 

Division of Extramural Activities, National 

Cancer Institute, 9609 Medical Center Drive, 

Room 7W244, Bethesda, MD 20892–9750, 

240–276–6373, bielatk@mail.nih.gov. 

Information is also available on the 

Institute’s/Center’s home page: http://

deainfo.nci.nih.gov/advisory/sep/sep.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: December 30, 2014. 

David Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–30879 Filed 1–5–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Initial 

Review Group; Neurological Sciences and 

Disorders B. 

Date: February 19–20, 2015. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hotel Monaco Alexandria, 480 King 

Street, Alexandria, VA 22314. 

Contact Person: Birgit Neuhuber, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

NINDS/NIH/DHHS/Neuroscience Center, 

6001 Executive Boulevard, Suite 3208, MSC 

9529, Bethesda, MD 20892–9529, 301–496– 

3562, neuhuber@ninds.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: December 30, 2014. 

Carolyn Baum, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–30875 Filed 1–5–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Cancer 

Institute Special Emphasis Panel, 

January 29, 2015 10:00 a.m. to January 

29, 2015, 05:00 p.m., National Cancer 

Institute Shady Grove, 9609 Medical 

Center Drive, Rockville, MD 20850 

which was published in the Federal 

Register on December 30, 2014, 

79FR78456. 

The meeting notice is being amended 

to change the title from Omnibus SEP– 

5 to Fundamental Mechanisms of 

Affective and Decisional Processes in 

Cancer Control. The meeting is closed to 

the public. 

Dated: December 30, 2014. 

David Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–30877 Filed 1–5–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel, NIAID Clinical Trial 

Implementation Cooperative Agreement 

(U01). 

Date: January 22, 2015. 

Time: 8:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Room 

3G62A, 5601 Fisher Lane, Rockville, MD 

20892, (Telephone Conference Call). 


tkelley on DSK3SPTVN1PROD with NOTICES